Search Results - Guillaume Lessene
- Showing 1 - 6 results of 6
-
1
-
2
Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. by Xinyu Wu, Shane M Devine, Margareta Go, Julie V Nguyen, Bernadine G C Lu, Katie Loi, Nathan W Kuchel, Kym N Lowes, Jeffrey P Mitchell, Guillaume Lessene, David Komander, Matthew E Call, Melissa J Call
Published in PLoS Pathogens (2025-09-01)Get full text
Article -
3
Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape by Xinyu Wu, Margareta Go, Julie V. Nguyen, Nathan W. Kuchel, Bernadine G. C. Lu, Kathleen Zeglinski, Kym N. Lowes, Dale J. Calleja, Jeffrey P. Mitchell, Guillaume Lessene, David Komander, Matthew E. Call, Melissa J. Call
Published in Nature Communications (2024-07-01)Get full text
Article -
4
Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis. by Zheng Yuan, Mark F van Delft, Mark Xiang Li, Fransisca Sumardy, Brian J Smith, David C S Huang, Guillaume Lessene, Yelena Khakam, Ruitao Jin, Sitong He, Nicholas A Smith, Richard W Birkinshaw, Peter E Czabotar, Grant Dewson
Published in PLoS Biology (2024-05-01)Get full text
Article -
5
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors by Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C. Chüeh, Judy Doherty, François Vaillant, Gwo-Yaw Ho, Matthew J. Wakefield, Clare E. Weeden, Alvin Kamili, Jayne Murray, Sela T. Po’uha, Janet Weinstock, Serena R. Kane, Maree C. Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J. Kershaw, Chin Wee Tan, Helen M. Witchard, Gregor Ebert, Susan A. Charman, Ian Street, Maria Kavallaris, Michelle Haber, Jamie I. Fletcher, Marie-Liesse Asselin-Labat, Clare L. Scott, Jane E. Visvader, Geoffrey J. Lindeman, Keith G. Watson, Antony W. Burgess, Guillaume Lessene
Published in Cell Death and Disease (2021-03-01)Get full text
Article -
6
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID by Stefanie M. Bader, Dale J. Calleja, Shane M. Devine, Nathan W. Kuchel, Bernadine G. C. Lu, Xinyu Wu, Richard W. Birkinshaw, Reet Bhandari, Katie Loi, Rohan Volpe, Yelena Khakham, Amanda E. Au, Timothy R. Blackmore, Liana Mackiewicz, Merle Dayton, Jan Schaefer, Lena Scherer, Angus T. Stock, James P. Cooney, Kael Schoffer, Ana Maluenda, Elizabeth A. Kleeman, Kathryn C. Davidson, Cody C. Allison, Gregor Ebert, Gong Chen, Kasiram Katneni, Theresa A. Klemm, Ueli Nachbur, Smitha Rose Georgy, Peter E. Czabotar, Anthony J. Hannan, Tracy L. Putoczki, Maria Tanzer, Marc Pellegrini, Bernhard C. Lechtenberg, Susan A. Charman, Melissa J. Call, Jeffrey P. Mitchell, Kym N. Lowes, Guillaume Lessene, Marcel Doerflinger, David Komander
Published in Nature Communications (2025-04-01)Get full text
Article
